HSP90AA1 and pulmonary arterial hypertension: Furthermore, it was established that the targeted inhibition of mitochondrial Hsp90 with Gamitrinib reversed pulmonary vascular remodeling and improved cardiac output in two PAH models without perceptible toxicity.